IBB UAB

News

Un equip de recerca de l’IBB-UAB i del Sincrotrón ALBA està desenvolupant un nou concepte de vacuna per protegir els peixos de piscifactoria de les principals malalties víriques que els afecten, basada en nanopartícules administrades per via oral.

Un equip de recerca de l’IBB-UAB i del Sincrotrón ALBA està desenvolupant un nou concepte de vacuna per protegir els peixos de piscifactoria de les principals malalties víriques que els afecten, basada en nanopartícules administrades per via oral.

News
Les malalties víriques són una de les majors preocupacions per a la indústria de l’aqüicultura. Una infecció en una piscifactoria pot contagiar-se molt fàcilment i causar estralls en tota la producció. Per aquest motiu els controls sanitaris són elevats i als peixos se’ls administren vacunes que, tanmateix, tenen certs inconvenients, com el cost de producció i administració o els riscos ambientals i de reversió de la malaltia. Per això s’estan buscant alternatives a les vacunes convencionals com la que ara investiga l’equip de la UAB al Sincrotró ALBA. “La vacuna que plantegem es basa en unes nanopartícules formades per proteïnes del virus que causa la malaltia” explica Nerea Roher, investigadora de l’Institut de Biotecnologia i de Biomedicina (IBB) i del Departament de Biologia Cel·lul
Una nueva investigación liderada por el Institut de Biotecnologia i de Biomedicina (IBB) de la Universitat Autònoma de Barcelona apunta directamente a una pequeña molécula conocida como SynoClean-D como posible freno a los procesos de neurodegeneración en modelos animales.

Una nueva investigación liderada por el Institut de Biotecnologia i de Biomedicina (IBB) de la Universitat Autònoma de Barcelona apunta directamente a una pequeña molécula conocida como SynoClean-D como posible freno a los procesos de neurodegeneración en modelos animales.

News
Identificada una molécula que detiene y revierte el Parkinson en animales     https://www.elperiodico.com/es/ciencia/20180924/identificada-una-molecula-que-detiene-el-parkinson-7050875  
Un nanofàrmac elimina selectivament cèl·lules mare metastàsiques en animals

Un nanofàrmac elimina selectivament cèl·lules mare metastàsiques en animals

News
    Una recerca publicada a Embo Molecular Medicineobre una nova via per prevenir la metàstasi en el càncer colorectal en humans utilitzant una nanomedicina que elimina selectivament les cèl·lules mare metastàsiques. Fins ara no hi ha fàrmacs al mercat que actuïn així.       Investigadors de la UAB, de l'Institut d'Investigació Biomèdica Sant Pau, de l'Hospital de la Santa Creu i Sant Pau, del Consell Superior d'Investigacions Científiques i del Centre de Recerca Biomèdica en Xarxa de Bioenginyeria, Biomaterials i Nanomedicina (CIBER-BBN) han publicat un article a una de les revistes científiques internacionals més prestigioses en l'àmbit de la medicina molecular, EMBO Molecular Medicine. Aquest article demostra l'eficàcia d'un nanofàrmac desenvolupat pels
Desarrollan el primer fármaco que elimina células madre metastásicas

Desarrollan el primer fármaco que elimina células madre metastásicas

News
  Se trata de un nanofármaco que abre una nueva vía para la prevención de la metástasis en el cáncer colorrectal   El nuevo fármaco funciona como un dron que identifica las células madre metastásicas, administra el fármaco y destruye únicamente estas células bloqueando la metástasis. De esta forma se evita la toxicidad general asociada a los tratamientos habituales, y se abre una nueva vía para prevenir la metástasis en el cáncer colorrectal. leer mas..
Dr. I. Roig : ATR is required to complete meiotic recombination in mice

Dr. I. Roig : ATR is required to complete meiotic recombination in mice

News
  Precise execution of recombination during meiosis is essential for forming chromosomally-balanced gametes. Meiotic recombination initiates with the formation and resection of DNA double-strand breaks (DSBs). Cellular responses to meiotic DSBs are critical for efficient repair and quality control, but molecular features of these remain poorly understood, particularly in mammals. Here we report that the DNA damage response protein kinase ATR is crucial for meiotic recombination and completion of meiotic prophase in mice. Using a hypomorphic Atr mutation and pharmacological inhibition of ATR in vivo and in cultured spermatocytes, we show that ATR, through its effector kinase CHK1, promotes efficient RAD51 and DMC1 assembly at RPA-coated resected DSB sites and establishment of interh...
Nanoligent, the spin off created by the Directors of Units 1 and 18 of NANBIOSIS, awarded for the best company in Health Sciences given by the law firm RCD

Nanoligent, the spin off created by the Directors of Units 1 and 18 of NANBIOSIS, awarded for the best company in Health Sciences given by the law firm RCD

News
NANOLIGENT is awarded for the best company in Health Sciences  Price given by the law firm RCD. The XXIII Investment Forum of ACCIÓ 2018 was celebrated last June 20th  with the aim of connecting with the world of private investment.  ACCIÓ, Company Competitiveness Agency, had previously published a catalog of startups with the most potential startups in Catalonia, projects selected from more than 100 candidatures were presented for the 2018 Investment Forum of ACTION. The 50 companies in this catalog stand out due to their differential nature and innovative value, due to their social impact and the involvement of the entrepreneurial team. They are companies operating in key sectors for the economy of the future such as life and health sciences, ICT and other crucial cutting-edge technolog
Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs

Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs

News
Abstract Loading capacity and drug leakage from vehicles during circulation in blood is a major concern when developing nanoparticle-based cell-targeted cytotoxics. To circumvent this potential issue it would be convenient the engineering of drugs as self-delivered nanoscale entities, devoid of any heterologous carriers. In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic materials targeted to CXCR4+ cancer stem cells. The systemic administration of both nanostructured drugs in a colorectal cancer xenograft mouse model promotes efficient and specific local destruction of target tumor tissues and a significant reduction of the tumor volume. This o...
Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin

Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin

News
  Abstract Under the unmet need of efficient tumor‐targeting drugs for oncology, a recombinant version of the plant toxin ricin (the modular protein T22‐mRTA‐H6) is engineered to self‐assemble as protein‐only, CXCR4‐targeted nanoparticles. The soluble version of the construct self‐organizes as regular 11 nm planar entities that are highly cytotoxic in cultured CXCR4+ cancer cells upon short time exposure, with a determined IC50 in the nanomolar order of magnitude. The chemical inhibition of CXCR4 binding sites in exposed cells results in a dramatic reduction of the cytotoxic potency, proving the receptor‐dependent mechanism of cytotoxicity. The insoluble version of T22‐mRTA‐H6 is, contrarily, moderately active, indicating that free, nanostructured protein is